Official UK procurement notice
NHS National Generic Pharmaceuticals Wave 13
Authority: The NHS Commissioning Board (operating under the name of NHS England) (NHS & healthcare)
What is being bought3 lots · detail below
Published requirement descriptionPotential periods of call-offs under the framework agreement:<br/><br/>Transition (Everolimus)<br/>CESW: 1 March 2022 – 30 September 2023 (19 months)<br/>LSNE: 1 March 2022 – 31 January 2023 (11 months)<br/>NWLN: 1 March 2022 – 31 January 2023 (11 months)<br/><br/>Oral Products plus non-parenterals<br/>All Regions: 1 March 2022 - 31 May 2024 (27 months)<br/><br/>Hospital Only Products<br/>CESW: 1 February 2022 – 30 September 2023 (20 months)<br/>LSNE: 1 February 2022 – 31 May 2024 (28 months)<br/>NWLN: 1 February 2022 – 31 January 2023 (12 months)
CPV: Pharmaceutical products
How this framework works
From the published notice- Bids received
- 124 bids on the busiest of 3 lots · 131 suppliers appointed
Lots and requirements (3)Procurement structure
3 lots · no lot values publishedLot #1CM/PHG/17/5532/00 Transition (Everolimus)Awarded
Invitation to offer for NHS National Generic Pharmaceuticals Wave 13<br/>Offer reference number: CM/PHG/17/5532<br/>Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority’s sole discretion) for a period or periods up to a total of 48 months.<br/><br/>Potential periods of call-offs under the framework agreement:<br/><br/>Transition (Everolimus)<br/>CESW: 1 March 2022 – 30 September 2023 (19 months)<br/>LSNE: 1 March 2022 – 31 January 2023 (11 months)<br/>NWLN: 1 March 2022 – 31 January 2023 (11 months)<br/><br/>Oral Products plus non-parenterals<br/>All Regions: 1 March 2022 - 31 May 2024 (27 months)<br/><br/>Hospital Only Products<br/>CESW: 1 February 2022 – 30 September 2023 (20 months)<br/>LSNE: 1 February 2022 – 31 May 2024 (28 months)<br/>NWLN: 1 February 2022 – 31 January 2023 (12 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Lot #2CM/PHG/17/5532/01 Oral Products plus non-parenteralsAwarded
Invitation to offer for NHS National Generic Pharmaceuticals Wave 13<br/>Offer reference number: CM/PHG/17/5532<br/>Period of framework agreement:The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority’s sole discretion) for a period or periods up to a total of 48 months.<br/><br/>Potential periods of call-offs under the framework agreement:<br/><br/>Transition (Everolimus)<br/>CESW: 1 March 2022 – 30 September 2023 (19 months)<br/>LSNE: 1 March 2022 – 31 January 2023 (11 months)<br/>NWLN: 1 March 2022 – 31 January 2023 (11 months)<br/><br/>Oral Products plus non-parenterals<br/>All Regions: 1 March 2022 - 31 May 2024 (27 months)<br/><br/>Hospital Only Products<br/>CESW: 1 February 2022 – 30 September 2023 (20 months)<br/>LSNE: 1 February 2022 – 31 May 2024 (28 months)<br/>NWLN: 1 February 2022 – 31 January 2023 (12 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Lot #3CM/PHG/17/5532/02 Hospital Only ProductsAwarded
Invitation to offer for NHS National Generic Pharmaceuticals Wave 13<br/>Offer reference number: CM/PHG/17/5532<br/>Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority’s sole discretion) for a period or periods up to a total of 48 months.<br/><br/>Potential periods of call-offs under the framework agreement:<br/><br/>Transition (Everolimus)<br/>CESW: 1 March 2022 – 30 September 2023 (19 months)<br/>LSNE: 1 March 2022 – 31 January 2023 (11 months)<br/>NWLN: 1 March 2022 – 31 January 2023 (11 months)<br/><br/>Oral Products plus non-parenterals<br/>All Regions: 1 March 2022 - 31 May 2024 (27 months)<br/><br/>Hospital Only Products<br/>CESW: 1 February 2022 – 30 September 2023 (20 months)<br/>LSNE: 1 February 2022 – 31 May 2024 (28 months)<br/>NWLN: 1 February 2022 – 31 January 2023 (12 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
What it takes to wini
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Evaluation split and conditions of participation as published; the tender pack may add morei
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
- “NHS National Generic Pharmaceuticals Wave 13” is a framework: the contest is a place on its panel, not a single contract.
Procedure terms & legal framework
From the official record · publisher note attached- Procedure method
- Open procedure
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Framework agreement
- Who may use this agreement
- Not stated in the notice; call-off rights may be limited to the establishing authority
- Competition type
- Competitive procedure
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- No (one-off requirement)
- First published
- 21 Jun 2021, 11:23 BST
- Last source update
- 14 Jan 2022, 10:31 GMT
- Award evaluation window
- 26 Jul 2021 – …
- Authority reference
CM/PHG/17/5532- FTS notice number
2022/S 000-001128- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-02be28Find a Tender
- Electronic trading
- e-invoicing allowed · electronic ordering · electronic payment
- Performance terms
See KPIs in procurement documents
Publisher note: RESPONDING TO THIS NOTICE;Any supplier may be disqualified who does not respond to the following in the requisite manner:1) Submission of expression of interest and procurement specific information. This procurement exercise will be conducted on the eTendering portal at http://health.atamis.co.ukCandidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific information (if requested) through the eTendering portal as follows:1.1) If not already registered, Candidates should register on the eTendering portal at http://health.atamis.co.uk and click the link to register:- agree to the user agreement- populate company details1.2) Once registered, candidates must register interest as follows:- log to the portal- select "Find Opportunities" from the supplier home screen, use the "Sort by:" facility to find this opportunity and select the bold blue title to select- review opportunity details and click "Register Interest"- as you select the opportunity, you can review documents, send clarification messages, submit the response or decline to respond (if you decide not to participate in the opportunity)1.3) There is a supplier user guide on using the system and Candidates can contact the Atamis helpdesk at [email protected] or by calling 0800 9956035 for technical assistance when completing responses.2) General supplier information.To manage and assess supplier information the Contracting Authority requests candidates provide theircompany profile in the Government's Supplier Registration Service (which has replaced sid4gov), as follows:2.1) If not already registered (the previous sid4gov password, login and details will stillbe on the system), candidates must go to the following web page https://supplierregistration.cabinetoffice.gov.ukand select "Register" at the top of the page.Key in details as requested to search for your company. If you do not have a D-U-N-S® Number, click on the link at the right of the page to obtain a number from D&B.Candidates must obtain a Dun & Bradstreet (D&B) D-U-N-S® Number to enable registration on the system.2.2) Once registration is complete you are able to create and update your company profile. Candidates should ensure all the mandatory fields of their profile are completed and up to date for each procurement exercise.D&B data will be supplied automatically by D&B.2.3) For further help or information concerning this telephone +44 (0) 161 413 7982 or via themessage function on the website.OTHER CONTRACTING AUTHORITIESThe framework agreement is for the benefit of other participating NHS bodies (whether acting individually, or on behalf of, or together as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare or health related services.
How it was run
Official noticeTender documents are also served through a separate tool: http://health.atamis.co.uk ↗
- Appointment period ends
- 26 Jul 2021, 13:00 BST
- Submission channel
- {"electronicSubmission","written"}
- Accepted languages
- en
- Bid validity
- 90 days from the deadline
- Bids opened
- 26 Jul 2021, 13:00 BST
Timeline
26 Jul 2021 → 14 Jan 2022 · 3 dates- Admission / appointment period endsperiod end, not a bid countdown26 Jul 2021, 13:00 BST
- Bids opened26 Jul 2021, 13:00 BST
- Notice published14 Jan 2022, 10:31 GMT
Notice history
1 event · 2 releases on Find a Tender- Status changed to complete14 Jan 2022, 10:31 GMT
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast192 suppliers are admitted to this framework without individual award values or dates, see the supplier list below.
Contracts
All 20 of these contracts carry the same published figure, £1, the framework's maximum for the whole notice, not each contract's own value. They are not eleven separate sums.
Lot 1 - CM/PHG/17/5532/00 Transition (Everolimus)
- Signed
- 30 Dec 2021
- Value
- ceiling above
- Status
- active
Lot 1 - CM/PHG/17/5532/00 Transition (Everolimus)
- Signed
- 30 Dec 2021
- Value
- ceiling above
- Status
- active
Lot 1 - CM/PHG/17/5532/00 Transition (Everolimus)
- Signed
- 30 Dec 2021
- Value
- ceiling above
- Status
- active
Lot 1 - CM/PHG/17/5532/00 Transition (Everolimus)
- Signed
- 30 Dec 2021
- Value
- ceiling above
- Status
- active
Lot 1 - CM/PHG/17/5532/00 Transition (Everolimus)
- Signed
- 30 Dec 2021
- Value
- ceiling above
- Status
- active
Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals
- Signed
- 30 Nov 2021
- Value
- ceiling above
- Status
- active
Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals
- Signed
- 30 Nov 2021
- Value
- ceiling above
- Status
- active
Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals
- Signed
- 30 Nov 2021
- Value
- ceiling above
- Status
- active
Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals
- Signed
- 30 Nov 2021
- Value
- ceiling above
- Status
- active
Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals
- Signed
- 30 Nov 2021
- Value
- ceiling above
- Status
- active
Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals
- Signed
- 30 Nov 2021
- Value
- ceiling above
- Status
- active
Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals
- Signed
- 30 Nov 2021
- Value
- ceiling above
- Status
- active
Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals
- Signed
- 30 Nov 2021
- Value
- ceiling above
- Status
- active
Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals
- Signed
- 30 Nov 2021
- Value
- ceiling above
- Status
- active
Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals
- Signed
- 30 Nov 2021
- Value
- ceiling above
- Status
- active
Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals
- Signed
- 30 Nov 2021
- Value
- ceiling above
- Status
- active
Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals
- Signed
- 30 Nov 2021
- Value
- ceiling above
- Status
- active
Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals
- Signed
- 30 Nov 2021
- Value
- ceiling above
- Status
- active
Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals
- Signed
- 30 Nov 2021
- Value
- ceiling above
- Status
- active
Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals
- Signed
- 30 Nov 2021
- Value
- ceiling above
- Status
- active
Bid statistics published by the authority
| Lot | Bids | SME | VCSE | Valid bid range |
|---|---|---|---|---|
| 1 · CM/PHG/17/5532/00 Transition (Everolimus) | 7bids · 7 electronic | — | — | — |
| 2 · CM/PHG/17/5532/01 Oral Products plus non-parenterals | 124bids · 124 electronic | — | — | — |
| 3 · CM/PHG/17/5532/02 Hospital Only Products | 114bids · 114 electronic | — | — | — |
Contracting authority & participating public bodies
Framework contractors & participating bidders
131 commercial parties on the notice · 50 awardedThe first 50 of 131 commercial parties (by name); the JSON mirror lists them all.
- ACIUM LTDFramework contractor
- AOP Orphan LtdFramework contractor
- Accord-UK LtdFramework contractor
- Aguettant LtdFramework contractor
- Alissa Healthcare Research LimitedFramework contractor
- AllerganFramework contractor
- Alliance Pharmaceuticals LimitedFramework contractor
- Altan Pharma LtdFramework contractor
- AlturixFramework contractor
- Amarox LimitedFramework contractor
Show 40 more suppliers
- Arcadia Pharma Ltd T/A Arcadia MedicalFramework contractor
- Aristo Pharma LimitedFramework contractor
- Ascend Laboratories UK LtdFramework contractor
- Aspen Pharmacare UK LimitedFramework contractor
- Aspire Pharma LimitedFramework contractor
- Atnahs Pharma UK LtdFramework contractor
- Aventis Pharma ltd t/a SanofiFramework contractor
- B. Braun Medical LimitedFramework contractor
- Baxter Healthcare LtdFramework contractor
- Bayer LtdFramework contractor
- Beaumont Pharma LtdFramework contractor
- Bowmed Ibisqus LimitedFramework contractor
- Bristol Laboratories LimitedFramework contractor
- Brown and Burk UK LtdFramework contractor
- CST Pharma LimitedFramework contractor
- Chiesi LimitedFramework contractor
- Cipla (EU) LtdFramework contractor
- Clydesdale Pharma ltdFramework contractor
- Colonis Pharma LtdFramework contractor
- Consilient Health LtdFramework contractor
- Correvio GmbHFramework contractor
- Crescent Pharma LtdFramework contractor
- Day Lewis Medical LtdFramework contractor
- Derma UKFramework contractor
- Desitin Pharma LtdFramework contractor
- Dexcel Pharma LtdFramework contractor
- Dr Falk Pharma UK LtdFramework contractor
- Dr.Reddy's Laboratories (UK) LimitedFramework contractor
- Drugsrus LtdFramework contractor
- Euro-Link Pharma LtdFramework contractor
- FLYNN PHARMA LTDFramework contractor
- Ferndale Pharmaceuticals LtdFramework contractor
- Ferring Pharmaceuticals LtdFramework contractor
- Flexipharm Austrading LimitedFramework contractor
- Focus Pharmaceuticals LtdFramework contractor
- Fontus Health LtdFramework contractor
- Fresenius Kabi LimitedFramework contractor
- Galen LimitedFramework contractor
- GlaxoSmithKline UK LimitedFramework contractor
- Glenmark Pharmaceuticals Europe LimitedFramework contractor
Official documents & specifications (1)
Official links; attachments are not copiedTender pack and attachments
- Economic and financial selection criteria